Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes

A Phase 2 Randomized Study to Evaluate the Effects of triamcinolone acetonide extended-release (TA-ER; Zilretta) vs. triamcinolone acetonide immediate-release (TA-IR; Kenalog) on Blood Glucose Levels in Diabetic Subjects with Knee Osteoarthritis. Subjects should have Type 2 Diabetes Mellitus (T2DM) with HbA1C ≤9 that is managed without insulin and have been diagnosed with symptomatic unilateral or bilateral osteoarthritis (OA) of the knee, based on clinical and radiological criteria (if bilateral, then a target knee will be selected).Total study duration for individual subject will be about 4 months, which includes 3 weeks of Screening period, 10 days of pretreatment phase, treatment day, and 12 weeks of post-treatment period.

NCT Number	NCT06478186
Lead Sponsor	University of Kansas Medical Center
Conditions	Osteoarthritis, Knee, Diabetes Mellitus, Type 2
Enrollment	120 participants
Start Date	2024-08-16
Primary Completion	2026-12-16 (estimated)
Study Completion	2027-01-16 (estimated)
Updated on ClinicalTrials.gov	2026-05-28